Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180740 | 0.81 | ALPL (0.36) | CYP3A4CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL1180679 | 0.76 | DDX3X (0.46) | AURKBAKT1KDM4ETHRBDGAT1 | |
| SCHEMBL21798839 | 0.66 | KDM4E (0.42) | CYP1A2CYP3A4CYP2C9CYP2C19CA12 | |
| SCHEMBL8097425 | 0.65 | CA12 (0.66) | CYP1A2CYP3A4CYP2C9CYP2C19CA12 | |
| SCHEMBL9909930 | 0.65 | NR1H2 (0.39) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL3243857 | 0.64 | ATR (0.42) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27497167 | 0.64 | NOS3 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL31188312 | 0.64 | KIF11 (0.44) | CYP1A2CYP2C19CA12CA1CA2 | |
| SCHEMBL6705858 | 0.63 | KMT2A (0.49) | CYP2C9CYP2C19GRM6GAAMEN1 | |
| SCHEMBL6177925 | 0.63 | CASP1 (0.41) | CYP3A4CYP2C9CYP2C19GRM6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | CYP1A2 2093/4885CYP3A4 2792/4885CYP2C9 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.